Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T. Shaw(Massachusetts General Hospital), Tae Min Kim(Seoul National University Hospital), Lucio Crinò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Katsuyuki Kiura(Okayama University Hospital), Geoffrey Liu(Princess Margaret Cancer Centre), Silvia Novello, Alessandra Bearz(Centro di Riferimento Oncologico), Oliver Gautschi(University of Lucerne), Tony Mok(Chinese University of Hong Kong), Makoto Nishio(Japanese Foundation For Cancer Research), Giorgio V. Scagliotti, David R. Spigel(Sarah Cannon), Stéphanie Deudon(Novartis (Switzerland)), Cheng Zheng(Novartis (United States)), Serafino Pantano(Novartis (Switzerland)), Patrick Urban(Novartis (Switzerland)), Cristian Massacesi(Novartis (Switzerland)), Kalyanee Viraswami-Appanna(Novartis (United States)), Enriqueta Felip(Vall d'Hebron Hospital Universitari)
Cited by 580Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis